AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 22 min read$QURE

Kaye Jack sold $983K of QURE

Kaye Jack sold 21,167 shares of uniQure N.V. (QURE) at an average of $46.44 ($46.43–$46.49, $0.98M total) across 2 trades on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kaye Jack
Published Jul 2, 2026, 8:54 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$QURE
Neutral
medium confidence
Mentioned
$QURE
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$QURENeutralLow
01

Why it matters

The newest concrete fact is the disclosed open-market sale size (~21,167 shares; ~$983K) by director Kaye Jack on 2026-06-30 under a 10b5-1 plan.

02

Market read

Insider-sale disclosures can influence short-term sentiment, but 10b5-1 plans usually reduce interpretive value versus discretionary selling.

03

What to watch

Traders may over-weight insider sales; without accompanying changes in guidance, trial results, or financing terms, the signal is typically weak.

Relevance 4/10Novelty 6/10Timing: filed after-hours on 2026-07-02; reflects trades dated 2026-06-30

Background

The article is a primary-source SEC Form 4 insider transaction for uniQure N.V. (QURE).

Company-level read

Ticker impact

$QURENeutralMedium confidence
Context

uniQure director Kaye Jack filed a Form 4 selling 21,167 shares in open-market trades on 2026-06-30 for ~$983K under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and fade unless accompanied by other company-specific news.

Evidence & confidence

The filing is a routine 10b5-1 open-market sale by a director, with no indication of new operational/regulatory/financial developments in the text.

Market effects

Sector

No sector read-through; this is company-specific insider transaction reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be mechanically scheduled and not a bearish signal.

Key entities

  • issuer
    uniQure N.V.

    Company whose director insider sale is disclosed via SEC Form 4.

  • insider
    Kaye Jack

    Director who sold 21,167 shares in two trades on 2026-06-30.

Read at source← All news

Related articles

AUG 8
$QUREMed

uniQure (QURE) Q2 2026 Earnings Call Transcript

uniQure (NASDAQ:QURE) reported Q2 2026 results and said the FDA aligned on submitting a Huntington’s disease AMT-130 BLA under accelerated approval in Q3 2026 using three-year data. Cash and investments were $810.3M at June 30, 2026 after a $259M follow-on. Q2 revenue was $5.8M, net loss $81.1M.

aol.com8 min
AUG 6
$QUREMed

Gene therapy shows benefits in all participants in Fabry clinical trial

uniQure said its investigational one-time gene therapy AMT-191 boosted alpha-galactosidase A levels in all 11 Fabry patients dosed in a Phase 1/2 U.S. trial (NCT06270316). All participants stopped enzyme replacement therapy. The company reported a manageable safety profile as of June, after prior liver enzyme elevations in two patients resolved with immunosuppression.

fabrydiseasenews.com5 min
JUL 29
$QUREMedAI 8/10

Why is uniQure stock surging today? By Investing.com

uniQure NV (QURE) shares rose about 6.3% pre-market after the company reported 2Q 2026 results and received July 2026 FDA meeting minutes confirming alignment that an AMT-130 BLA submission under accelerated approval using existing clinical data is reasonable. Revenue was $5.84M vs ~$5.49M consensus. uniQure also raised $259M via follow-on offering, extending cash runway to 2030.

investing.com6 min
JUL 29
$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update

uniQure N.V. (NASDAQ: QURE) reported Q2 2026 results and updated its gene therapy pipeline. It said FDA alignment supports a Q3 2026 BLA submission for AMT-130 in Huntington’s disease, with four-year Phase I/II data planned for September 2026. For AMT-260, early Phase I/IIa cohort data showed seizure reductions and no AMT-260 related SAEs. uniQure raised $259M via a follow-on offering, extending cash runway into 2030. Q2 revenue was $5.8M.

finanznachrichten.de6 min
JUL 29
$QUREMed

uniQure N.V. (QURE): Results of Operations and Financial Condition

uniQure N.V. (QURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qure-20260729xex99d1.htm EX-99.1 Exhibit 99.1 uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline fo

SEC EDGAR 8-K6 min
JUN 25
$QUREMedAI 8/10

uniQure Inc.: uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

uniQure N.V. (Nasdaq: QURE) said it closed an upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 each, including 741,758 shares from full exercise of the underwriters’ option. Gross proceeds were about $259 million before underwriting fees and expenses. Net proceeds will fund AMT-130 commercialization readiness, a confirmatory study, other clinical programs, business development, and general corporate purposes.

finanznachrichten.de2 min